Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 27

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 27
---
2,374  
     1,192 
  
    Exercise of warrants for common stock 
     3,405,479  
     101,602  
     - 
  
    Common stock underlying outstanding options (2024 Plan) 
     471,199  
     46,194  
     504 

     6,444,918  
     160,711  
     19,691 

Restricted common stock can
be issued to directors, executives or employees of the Company and are subject to time-based vesting. These potential shares are excluded
from the computation of basic loss per share as these shares are not considered outstanding until vested. No unvested restricted common
stock awards were issued or outstanding during the three months ended March 31, 2025 or 2024. 

NOTE 5 – PROPERTY AND
EQUIPMENT

Property and equipment, net, consisted of the
following as of March 31, 2025 and December 31, 2024:

    March 31,  
    December 31, 

    2025  
    2024 

    (Successor)  
    (Successor) 
  
    Laboratory equipment 
    $2,507,839  
    $2,507,839 
  
    Computers 
     38,323  
     38,323 
  
    Furniture 
     8,429  
     8,429 
  
    Total cost 
     2,554,591  
     2,554,591 
  
    Less: accumulated depreciation 
     (2,102,364) 
     (2,026,070)
  
    Property and equipment, net 
    $452,227  
    $528,521 

Depreciation expense for
the three months ended March 31, 2025 was $76,294 and for period from February 14, 2024 through March 31, 2024 for Successor was $76,287.
Predecessor depreciation expense for the period January 1, 2024 through February 13, 2024 was $37,356.

14

NOTE 6 – ACCRUED LIABILITIES

Accrued liabilities consisted of the following as of March
31, 2025 and December 31, 2024:

    March 31,  
    December 31,